Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer

Siegel, 2020, Cancer statistics, 2020, CA Cancer J Clin, 70, 7, 10.3322/caac.21590 Bagheri, 2017, Advances in medical imaging for the diagnosis and management of common genitourinary cancers, Urol Oncol, 35, 473, 10.1016/j.urolonc.2017.04.014 2020 Weinreb, 2021, Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation, Kidney Med, 3, 142, 10.1016/j.xkme.2020.10.001 Panebianco, 2018, Multiparametric magnetic resonance imaging for bladder cancer:dDevelopment of VI-RADS (Vesical Imaging-Reporting And Data System), Eur Urol, 74, 294, 10.1016/j.eururo.2018.04.029 Civelek, 2016, 18F-FDG PET-MRI in the management of muscle invasive bladder cancer: Challenges in imaging and solutions, J Nucl Med, 57 Malayeri, 2015, Imaging muscle-invasive and metastatic urothelial carcinoma, Curr Opin Urol, 25, 441, 10.1097/MOU.0000000000000208 Apolo, 2010, Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer, J Clin Oncol, 28, 3973, 10.1200/JCO.2010.28.7052 Farwell, 2014, PET/CT imaging in cancer: current applications and future directions, Cancer, 120, 3433, 10.1002/cncr.28860 Zattoni, 2019, (18)F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study, Cancers., 11, 700, 10.3390/cancers11050700 Kitajima, 2016, FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT, Eur J Radiol, 85, 593, 10.1016/j.ejrad.2015.12.017 Lu, 2012, Clinical value of FDG PET or PET/CT in urinary bladder cancer: A systemic review and meta-analysis, Eur J Radiol, 81, 2411, 10.1016/j.ejrad.2011.07.018 Al-Nabhani, 2014, Qualitative and quantitative comparison of PET/CT and PET/MR imaging in clinical practice, J Nucl Med, 55, 88, 10.2967/jnumed.113.123547 Tan, 2020, Total-Body PET/CT: Current Applications and Future Perspectives, AJR Am J., 215, 325, 10.2214/AJR.19.22705 Bagheri, 2017, Advances in medical imaging for the diagnosis and management of common genitourinary cancers, Urol Oncol, 35, 473, 10.1016/j.urolonc.2017.04.014 Krishnasetty, 2008, Comparison of Standard-Dose vs Low-Dose Attenuation Correction CT on Image Quality and Positron Emission Tomographic Attenuation Correction, J Am Coll Radiol, 5, 579, 10.1016/j.jacr.2007.12.007 de Haas, 2014, Multiparametric MRI of the Bladder: Ready for Clinical Routine?, AJR Am J, 202, 1187, 10.2214/AJR.13.12294 Berthelsen, 2005, PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients, Eur J Nucl Med Mol Imaging, 32, 1167, 10.1007/s00259-005-1784-1 Costa, 2008, Body MRI using IDEAL, AJR Am J Roentgenol, 190, 1076, 10.2214/AJR.07.3182 Rosenkrantz, 2015, Comparison of Coregistration Accuracy of Pelvic Structures Between Sequential and Simultaneous Imaging During Hybrid PET/MRI in Patients with Bladder Cancer, Clin Nucl Med, 40, 637, 10.1097/RLU.0000000000000772 Rosenkrantz, 2017, Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI, Clin Nucl Med, 42, e8, 10.1097/RLU.0000000000001432 Mayerhoefer, 2020, PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations, Eur J Nucl Med Mol Imaging, 47, 51, 10.1007/s00259-019-04452-y